EAN 2026: Positive trial data for cemdisiran underscores potential for use in generalized MG, says GlobalData
From the article
On June 30, at the 12th Congress of the European Academy of Neurology (EAN) 2026, Regeneron announced the results from an additional analysis of the Phase III NIMBLE study of cemdisiran for generalized myasthenia gravis (gMG). The positive results highlight the potential for use of cemdisiran in this patient segment, according to GlobalData, a leading […]
Continue reading on globaldata.comYou might also wanna read
Unequal Access to New Myasthenia Gravis Therapies Across Europe Highlights Healthcare Disparities
This article examines the growing gap between medical innovation and patient access in the treatment of generalised myasthenia gravis (gMG)
euractiv.com·13d agoSexual and Urinary Dysfunctions in Generalized Myasthenia
clinicaltrials.gov·8d ago
ADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlights
In this JAMA Medical News podcast, Jennifer Abbasi interviews Dr. Rita Kalyani, the ADA's Chief Scientific and Medical Officer, about key hi
ja.ma·18d ago
ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted
An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scient
ja.ma·19d agoGSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
GSK·17y ago
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK·17y ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.